Genmab - ADR

NASDAQ:GMAB  
42.96
-0.57 (-1.31%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)28.10B
Current PE5.03
Forward PE 79.56
2yr Forward PE 58.05
See more stats
Estimates Current Quarter
Revenue$272.4 Million
Adjusted EPS$0.08
See more estimates
10-Day MA$43.03
50-Day MA$38.57
200-Day MA$37.56
See more pivots

Genmab - ADR Stock, NASDAQ:GMAB

Kalvebod Brygge 43, Copenhagen, Capital Region 1560
Phone: +45.70.20.27.28
Number of Employees: 781

Description

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.